CORONA Remedies: The financial results for the period ended September 30, 2026
CORONA Remedies (CORONA) filed a disclosure titled "The financial results for the period ended September 30, 2026". The company is valued at about ₹13,562 crore.
What happened
CORONA Remedies (CORONA) filed a disclosure with the exchanges on 30 October 2026 at 06:35 PM titled "The financial results for the period ended September 30, 2026".
Company snapshot
CORONA Remedies is a small-cap company in the Healthcare sector, with a market value of about ₹13,562 crore.
The stock last traded at ₹2,217.4, against a 52-week range of ₹1,336.6–₹2,292.4 (3.3% below the high).
Before this filing the shares had moved +8.0% over the month and +6.0% over three months. Average daily turnover over the last 20 sessions was about ₹5.18 crore.
Promoters held 69.00% at the end of Q1 FY27. Foreign institutions owned 3.63% and domestic institutions 12.90%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q2 FY26 | 361 | 52.3 | 8.55 |
| Q3 FY26 | 342 | 41.3 | 6.75 |
| Q4 FY26 | 353 | 45.3 | 7.41 |
| Q1 FY27 | 422 | 60.1 | 9.83 |
What history shows
This is not the company's first results disclosure: BCEIE has 3 earlier filings of this kind on record since May 2026.
After those filings, the stock gained 2.5% on average the next trading day and was up 0.9% on average after five days (2 filings with price data).
Across 300 similar disclosures by other Healthcare companies, shares moved +1.0% on average the next day and +1.8% over five days; 55% of them rose the next day.
Market-wide, 10,043 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 7 Aug 2026 | 'Machine Readable Financial results for Q1 2026-27'. | +2.1% | +2.6% |
| 31 Jul 2026 | Unaudited Financial Results For The First Quarter And Three Months… | +2.9% | −0.8% |
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
- 30 October 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
- Earnings To Watch: Corona Remedies Ltd (NSE:CORONA) Reports Q2 2027 Result
- Corona Remedies Limited Estimates – NSE:CORONA
- CORONA Remedies Secures ANVISA GMP Certification For Bhayla Facility
- Earnings To Watch: Corona Remedies Ltd (NSE:CORONA) Reports Q2 2
- CORONA Remedies secures Brazil’s ANVISA GMP certification for Bhayla facility
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.